As of Mar 30
| -0.81 / -3.47%|
The 9 analysts offering 12-month price forecasts for Myriad Genetics Inc have a median target of 20.00, with a high estimate of 27.00 and a low estimate of 13.00. The median estimate represents a -11.19% decrease from the last price of 22.52.
The current consensus among 9 polled investment analysts is to Hold stock in Myriad Genetics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.